Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

Antiretroviral therapy (ART) inhibits HIV replication but is not curative. During ART, the
integrated HIV genome persists indefinitely within CD4+ T cells and perhaps other cells …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

A latent reservoir for HIV-1 in resting CD4+ T lymphocytes precludes cure. Mechanisms
underlying reservoir stability are unclear. Recent studies suggest an unexpected degree of …

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

HIV persists in a small pool of latently infected cells despite antiretroviral therapy (ART).
Identifying cellular markers expressed at the surface of these cells may lead to novel …

Antiretroviral therapy fails to cure HIV-1 infection because latent proviruses persist in resting
CD4+ T cells. T cell activation reverses latency, but< 1% of proviruses are induced to …

Despite antiretroviral therapy, HIV-1 persists in memory CD4+ T cells, creating a barrier to
cure. The majority of HIV-1 proviruses are defective and considered clinically irrelevant …

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

We employed an RNA-guided CRISPR/Cas9 DNA editing system to precisely remove the
entire HIV-1 genome spanning between 5′ and 3′ LTRs of integrated HIV-1 proviral DNA …